Results 271 to 280 of about 6,446,269 (330)
Reading the Metal Diaries of the Universe: Tracing Cosmic Chemical Evolution [PDF]
, 2009 D. H. Hartmann, C. Kouveliotou, L. Piro, J. W. den Herder, T. Ohashi, Tom Abel, L. Amati, S. D. Barthelmy, J. F. Beacom, J. S. Bloom, Massimiliano Bonamente, E. Branchini, G. Branduardi‐Raymont, Joel N. Bregman, M. S. Briggs, Volker Bromm, Andreas Burkert, D. Burrows, S. Campana, C. Carilli, Renyue Cen, P. Coppi, Charles Danforth, R. Diehl, S. Ettori, S. Michael Fall, X. Fan, G. J. Fishman, Brian D. Fields, C. Jones Forman, G. Ghisellini, M. Galeazzi, N. Gehrels, G. Ghirlanda, J. E. Grindlay, Alexander Heger, Patrick Henry, W. Hermsen, Andrew D. Holland, John P. Hughes, J. S. Kaastra, N. Kawai, Bill Keel, Richard L. Kelley, M. Kippen, Alexander Kusenko, Abraham Loeb, Piero Madau, F. Matteuccí, Grant J. Mathews, C. Meegan, P. Mészáros, T. Mineo, K. Mitsuda, S. Molendi, L. Natalucci, K. Nomoto, P. T. O’Brien, Stephen L. O’Dell, F. Paerels, Giovanni Pareschi, V. Petrosian, Nikos Prantzos, Joel R. Primack, J. X. Prochaska, E. Ramirez‐Ruiz, B. D. Ramsey, Andrew Rasmussen, S. Savaglio, Joop Schaye, S. L. Snowden, Volker Springel, Yasushi Suto, G. Tagliaferri, Yoh Takei, Yuzuru Tawara, F. X. Timmes, L. K. Townsely, P. Ubertini, A. J. van der Horst, Jacco Vink, M. C. Weisskopf, R. A. M. J. Wijers, C. Wilson‐Hodge, S. E. Woosley, Noriko Y. Yamasaki +85 moreopenalex LINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma
Molecular Oncology, EarlyView.The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...Marine Gautier‐Isola, Rafael Lopes Goncalves, Marin Truchi, Caroline Lacoux, Célia Scribe, Hugo Cadis, Laetitia Guardini, Sophie Bekisz, Marius Ilié, Paul Hofman, Georges Vassaux, Bernard Mari, Roger Rezzonico +12 morewiley +1 more sourceATF4‐mediated stress response as a therapeutic vulnerability in chordoma
Molecular Oncology, EarlyView.We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs +11 morewiley +1 more sourceOperando Multi-modal Synchrotron Investigation for Structural and Chemical Evolution of Cupric Sulfide (CuS) Additive in Li-S battery. [PDF]
Sci Rep, 2017 Sun K, Zhao C, Lin CH, Stavitski E, Williams GJ, Bai J, Dooryhee E, Attenkofer K, Thieme J, Chen-Wiegart YK, Gan H. +10 moreeuropepmc +1 more sourceA subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy
Molecular Oncology, EarlyView.Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli +3 morewiley +1 more sourceDeveloping evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities
Molecular Oncology, EarlyView.The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking +43 morewiley +1 more sourceTherapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition
Molecular Oncology, EarlyView.We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida +10 morewiley +1 more sourceInfrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma
Molecular Oncology, EarlyView.Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn +11 morewiley +1 more sourceRecurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies
Molecular Oncology, EarlyView.We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa +15 morewiley +1 more sourceCrucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples
Molecular Oncology, EarlyView.This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.Hanne Goris, Vasiliki Siozopoulou, Léon C van Kempen, Anne Sieben, Ella Roelant, Stig Hellemans, Elyne Backx, Laure Sorber, Koen De Winne, Senada Koljenović, Karen Zwaenepoel +10 morewiley +1 more source
